menu
    • menu
    [{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":1.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.25,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"SRI International \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"3","companyTruncated":"SRI International \/ Janssen Pharmaceutica"},{"orgOrder":0,"company":"AbSci","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Enzyme","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"AbSci \/ Merck"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Amgen","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Amgen"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Cell Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Artisan Development Labs Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Artisan Development Labs Inc."},{"orgOrder":0,"company":"Gandeeva Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Precision Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gandeeva Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Gandeeva Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Gandeeva Therapeutics \/ Lux Capital"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"VHH Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Abcam","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Abcam"},{"orgOrder":0,"company":"Eighteen Fifty-Nine","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Eighteen Fifty-Nine","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Eighteen Fifty-Nine \/ Northpond Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Eighteen Fifty-Nine \/ Northpond Ventures"},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Macromolecules","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"i2o Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"i2o Therapeutics \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"i2o Therapeutics \/ Janssen"},{"orgOrder":0,"company":"Excelra","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Excelra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Excelra \/ X-Chem","highestDevelopmentStatusID":"2","companyTruncated":"Excelra \/ X-Chem"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"WuXi AppTec \/ Orbit Discovery"},{"orgOrder":0,"company":"Specifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Specifica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Specifica \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Specifica \/ Not Applicable"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Sanofi"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"LifeMine Therapeutics \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Recombinant Human Hyaluronidase PH20 Enzyme","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Halozyme Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.19,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Chugai","highestDevelopmentStatusID":"1","companyTruncated":"Halozyme Therapeutics \/ Chugai"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"LNC-based mRNA Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"VantAI \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"SLN-HAN-1","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharmaceutical"},{"orgOrder":0,"company":"Apertura Gene Therapy","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Apertura Gene Therapy","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Apertura Gene Therapy \/ Deerfield Management Company","highestDevelopmentStatusID":"2","companyTruncated":"Apertura Gene Therapy \/ Deerfield Management Company"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ GC Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ GC Biopharma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ A*STAR's Bioprocessing Technology Institute"},{"orgOrder":0,"company":"Empirico","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Antibody-based Therapy","moa":"GPCR","graph1":"Technology","graph2":"Discovery Platform","graph3":"Empirico","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Empirico \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Empirico \/ AbCellera"},{"orgOrder":0,"company":"Illumina","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"Illumina \/ Deerfield Management","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ Deerfield Management"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Editing Oligonucleotides","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ProQR Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anagenex","sponsor":"Catalio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Anagenex \/ Catalio","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Catalio"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Janssen","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Janssen"},{"orgOrder":0,"company":"xFOREST Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"xFOREST Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"xFOREST Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"xFOREST Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Sanyou Biopharmaceuticals \/ Dragon Sail Pharmaceutical"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Technology","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cronos Group \/ Geocann","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Geocann"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Touchlight \/ Pfizer"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Ring Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kyowa Pharmaceutical Industry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Kyowa Pharmaceutical Industry \/ Bora Pharmaceutical Laboratories"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Thorne HealthTech \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Thorne HealthTech \/ AstraZeneca"},{"orgOrder":0,"company":"Starpharma","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ MSD","highestDevelopmentStatusID":"1","companyTruncated":"Starpharma \/ MSD"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Celesta Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series C Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Prellis Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Prellis Biologics \/ Celesta Capital","highestDevelopmentStatusID":"3","companyTruncated":"Prellis Biologics \/ Celesta Capital"},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ BioDuro-Sundia","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ BioDuro-Sundia"},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Beta-lactoglobulin","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Zerion Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Zerion Pharma \/ Hovione","highestDevelopmentStatusID":"4","companyTruncated":"Zerion Pharma \/ Hovione"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"OmniAb \/ Avista Public Acquisition Corp. II","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Avista Public Acquisition Corp. II"},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Emergence","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Emergence"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"RNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Orbital Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Orbital Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series C Financing","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Forge Biologics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Forge Biologics \/ Drive Capital","highestDevelopmentStatusID":"1","companyTruncated":"Forge Biologics \/ Drive Capital"},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Recombinant Human Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Department of Defense","highestDevelopmentStatusID":"3","companyTruncated":"GigaGen \/ Department of Defense"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Cytoreason","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.11,"dosageForm":"","sponsorNew":"Cytoreason \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Cytoreason \/ Pfizer"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"mRNA","graph1":"Technology","graph2":"Preclinical","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"Vanda Pharmaceuticals \/ OliPass"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series D Financing","leadProduct":"In-vivo Human Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ 8VC","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ 8VC"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"mRNA-based Regenerative Medicine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Pantherna Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Pantherna Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Pantherna Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Circular RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Circularis Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Circularis Biotechnologies \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Circularis Biotechnologies \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories, Inc \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Illumina","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Illumina","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Illumina \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Illumina \/ AstraZeneca"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Dualsystems Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Dualsystems Biotech","highestDevelopmentStatusID":"2","companyTruncated":"aTyr Pharma \/ Dualsystems Biotech"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"VectorBuilder","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VectorBuilder \/ Legend Capital","highestDevelopmentStatusID":"1","companyTruncated":"VectorBuilder \/ Legend Capital"},{"orgOrder":0,"company":"XtalPi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"XtalPi \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Recombinant Polyclonal Antibody","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ GigaGen","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic \/ GigaGen"},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Demerger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"OmniAb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"OmniAb \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"OmniAb \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV Vectors","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Advanced Therapies \/ Janssen","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Advanced Therapies \/ Janssen"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Sanofi"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Metagenomi \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Voyager Therapeutic","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Voyager Therapeutic"},{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Beacon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Beacon Discovery \/ Eurofins","highestDevelopmentStatusID":"2","companyTruncated":"Beacon Discovery \/ Eurofins"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"SonoThera","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"SonoThera \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"SonoThera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Entactbio","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Entactbio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Entactbio \/ 4BIO Capital","highestDevelopmentStatusID":"2","companyTruncated":"Entactbio \/ 4BIO Capital"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Infinimmune","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Infinimmune \/ Playground Global","highestDevelopmentStatusID":"2","companyTruncated":"Infinimmune \/ Playground Global"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Parallel Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Parallel Bio \/ Refactor Capital","highestDevelopmentStatusID":"2","companyTruncated":"Parallel Bio \/ Refactor Capital"},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alteogen \/ Sandoz","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Sandoz"},{"orgOrder":0,"company":"OriCiro Genomics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"OriCiro Genomics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"OriCiro Genomics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"OriCiro Genomics \/ Moderna"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Belharra Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Belharra Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Belharra Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":2,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":2,"dosageForm":"","sponsorNew":"Synaffix \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Amgen Inc"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"IntoCell","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"IntoCell \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IntoCell \/ ADC Therapeutics"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":1.1200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.1200000000000001,"dosageForm":"","sponsorNew":"Nimble Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Synaffix \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ Hummingbird Bioscience"},{"orgOrder":0,"company":"Harbor Discoveries","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Harbor Discoveries","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Harbor Discoveries \/ Deerfield Management","highestDevelopmentStatusID":"2","companyTruncated":"Harbor Discoveries \/ Deerfield Management"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"AskBio","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AskBio \/ ReCode Therapeutics"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.68999999999999995,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ National Resilience","highestDevelopmentStatusID":"1","companyTruncated":"Matinas BioPharma \/ National Resilience"},{"orgOrder":0,"company":"MicrofluidX","sponsor":"CCRM","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"mRNA-based CART-cell Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"MicrofluidX","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"MicrofluidX \/ CCRM","highestDevelopmentStatusID":"2","companyTruncated":"MicrofluidX \/ CCRM"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Cristal Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ Cristal Therapeutics"},{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cryoport Systems Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Cryoport Systems Inc \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Cryoport Systems Inc \/ Syneos Health"},{"orgOrder":0,"company":"Neochromosome","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Neochromosome \/ Sumitovant Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Neochromosome \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ McSAF","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ McSAF"},{"orgOrder":0,"company":"Atomic AI","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomic AI","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Atomic AI \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Atomic AI \/ Playground Global"},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Engineered Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.8999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Amgen Inc"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"Protein","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1.28,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"Inhalation","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Molecular glue","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.55000000000000004,"dosageForm":"","sponsorNew":"Proxygen \/ Merck Group","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck Group"},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":1.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.02,"dosageForm":"","sponsorNew":"Atomwise \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ Sanofi"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"PeptiDream \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Eli Lilly"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Insilico Medicine","amount2":1.22,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.22,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Insilico Medicine \/ Sanofi"},{"orgOrder":0,"company":"PeptiDream","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.1000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"PeptiDream \/ MSD","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ MSD"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Duquesne Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Ratio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.02,"dosageForm":"","sponsorNew":"Ratio Therapeutics \/ Duquesne Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ratio Therapeutics \/ Duquesne Capital"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.58999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Synaffix \/ MacroGenics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/ MacroGenics"},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Generian Pharmaceuticals \/ Mitobridge","highestDevelopmentStatusID":"3","companyTruncated":"Generian Pharmaceuticals \/ Mitobridge"},{"orgOrder":0,"company":"Bio Immunitas","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Bio Immunitas","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Bio Immunitas \/ GenScript ProBio","highestDevelopmentStatusID":"3","companyTruncated":"Bio Immunitas \/ GenScript ProBio"},{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ablexis","highestDevelopmentStatusID":"3","companyTruncated":"Adimab \/ Ablexis"},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Related Sciences"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Merck"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Schrodinger","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Schrodinger \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinger \/ Eli Lilly"},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Life Edit Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Life Edit Therapeutics \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Life Edit Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Oligonucleotide","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Summit Pharmaceuticals Europe Srl"},{"orgOrder":0,"company":"TandemAI","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"TandemAI","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"TandemAI \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"TandemAI \/ Qiming Venture Partners"},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Chroma Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Chroma Medicine \/ Google Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Chroma Medicine \/ Google Ventures"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"IND Enabling","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Touchlight \/ Not Applicable"},{"orgOrder":0,"company":"Charles River Laboratories International","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Charles River Laboratories International","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Charles River Laboratories International \/ Pioneering Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Charles River Laboratories International \/ Pioneering Medicines"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Human Cellular Medicine","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Kytopen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Kytopen \/ Mirus Bio","highestDevelopmentStatusID":"1","companyTruncated":"Kytopen \/ Mirus Bio"},{"orgOrder":0,"company":"Antiverse","sponsor":"InnoSpark","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Antiverse \/ InnoSpark","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ InnoSpark"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Janssen Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Janssen Biotech"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series C Financing","leadProduct":"Anellovirus-based Therapy","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Ring Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Ring Therapeutics \/ Alexandria Venture Investments","highestDevelopmentStatusID":"4","companyTruncated":"Ring Therapeutics \/ Alexandria Venture Investments"},{"orgOrder":0,"company":"AbCheck","sponsor":"Czech Republic","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Czech Republic","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Czech Republic"},{"orgOrder":0,"company":"Seamless Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Seamless Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Seamless Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seamless Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"CHARM Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"CHARM Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"CHARM Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Arzeda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Arzeda \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Arzeda \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Genetic Medicine","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Generation Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Generation Bio \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"Generation Bio \/ Moderna"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xeris Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRIA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Proxygen","amount2":2.5499999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Proxygen \/ Merck & Co. Inc.","highestDevelopmentStatusID":"2","companyTruncated":"Proxygen \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Astellas Pharma"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Eterna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Eterna Therapeutics \/ Lincoln Park Capital","highestDevelopmentStatusID":"1","companyTruncated":"Eterna Therapeutics \/ Lincoln Park Capital"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Antibody Drug Conjugate","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Samsung Venture Investment Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Araris Biotech \/ Samsung Venture Investment Corporation"},{"orgOrder":0,"company":"Center for iPS Cell Research and Application","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"iPS cell-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Center for iPS Cell Research and Application","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Center for iPS Cell Research and Application \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Center for iPS Cell Research and Application \/ Astellas Pharma"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Rubic One Health","highestDevelopmentStatusID":"3","companyTruncated":"Dyadic International, Inc \/ Rubic One Health"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Veneno Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Veneno Technologies \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Veneno Technologies \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"FAP-2286","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"3B Pharmaceuticals","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"3B Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Series A Financing","leadProduct":"RNA-based therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbital Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Orbital Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Orbital Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Initial Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Initial Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Initial Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Initial Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Targeted Protein Degradation Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1.28,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.28,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cyclica \/ Recursion Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Recursion Pharma"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Just \u2013 Evotec Biologics","amount2":0.64000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Sandoz B2B","highestDevelopmentStatusID":"1","companyTruncated":"Just \u2013 Evotec Biologics \/ Sandoz B2B"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"DyNAbind","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ DyNAbind","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ DyNAbind"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"mRNA-based Vaccine","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Matinas BioPharma \/ BioNTech"},{"orgOrder":0,"company":"Thousand Oaks Biologics","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Thousand Oaks Biologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Thousand Oaks Biologics \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"Thousand Oaks Biologics \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint Neuro \/ UCB Pharma S.A"},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ AyurMaya Capital Management Fund"},{"orgOrder":0,"company":"AstriVax","sponsor":"VLAIO","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"BELGIUM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstriVax","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AstriVax \/ VLAIO","highestDevelopmentStatusID":"3","companyTruncated":"AstriVax \/ VLAIO"},{"orgOrder":0,"company":"XtalPi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.25,"dosageForm":"","sponsorNew":"XtalPi \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Eli Lilly"},{"orgOrder":0,"company":"aVaxziPen","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Protein-based Vaccine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"aVaxziPen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"aVaxziPen \/ CEPI","highestDevelopmentStatusID":"3","companyTruncated":"aVaxziPen \/ CEPI"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"BIOKEY","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undislcosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Merdury Pharmaceutical \/ BioKey","highestDevelopmentStatusID":"3","companyTruncated":"Merdury Pharmaceutical \/ BioKey"},{"orgOrder":0,"company":"Iktos","sponsor":"Curreio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Curreio","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Curreio"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"BELGIUM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"GPCR Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Confo Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Acuitas \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Bayer AG"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Oligonucleotide Drug","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Doer Biologics \/ BioNTech","highestDevelopmentStatusID":"2","companyTruncated":"Zhejiang Doer Biologics \/ BioNTech"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"siRNA","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.3200000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"Pioneering Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Pioneering Medicines","amount2":0.80000000000000004,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Pioneering Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Pioneering Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Chroma Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Epigenetic Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Chroma Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Sangamo Therapeutics \/ Chroma Medicine"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Protein Degrader Drug","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0.75,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.75,"dosageForm":"","sponsorNew":"PeptiDream \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Astellas Pharma"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InstaDeep","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.68999999999999995,"dosageForm":"","sponsorNew":"InstaDeep \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"InstaDeep \/ BioNTech"},{"orgOrder":0,"company":"CAS","sponsor":"Molecule.one","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"CAS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"CAS \/ Molecule.one","highestDevelopmentStatusID":"2","companyTruncated":"CAS \/ Molecule.one"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genesis Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Andreessen Horowitz","highestDevelopmentStatusID":"3","companyTruncated":"Genesis Therapeutics \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Superluminal Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Superluminal Medicines \/ RA Capital","highestDevelopmentStatusID":"2","companyTruncated":"Superluminal Medicines \/ RA Capital"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Tentarix Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Septerna","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Septerna","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Septerna \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Septerna \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ BeiGene"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Peptide-radioisotope Drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"PeptiDream \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"PeptiDream \/ Genentech"},{"orgOrder":0,"company":"BioLoomics","sponsor":"Innovation Endeavors","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"BioLoomics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"BioLoomics \/ Innovation Endeavors","highestDevelopmentStatusID":"2","companyTruncated":"BioLoomics \/ Innovation Endeavors"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Partillion Bioscience","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Partillion Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Partillion Bioscience \/ Alloy Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Partillion Bioscience \/ Alloy Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"AAV Gene Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Medicinova","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Medicinova \/ Sanofi Genzyme","highestDevelopmentStatusID":"1","companyTruncated":"Medicinova \/ Sanofi Genzyme"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Icosagen","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWEDEN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Icosagen","highestDevelopmentStatusID":"2","companyTruncated":"Salipro Biotech \/ Icosagen"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bispecific Antibody","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"EpimAb Biotherapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"EpimAb Biotherapeutics \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"EpimAb Biotherapeutics \/ Almirall"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":1.03,"dosageForm":"","sponsorNew":"Sosei Heptares \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Genentech"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bioconjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Nona Biosciences"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Cannabinoid-based Therapeutic","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Cannasoul","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Cannasoul \/ Synaptogenix","highestDevelopmentStatusID":"1","companyTruncated":"Cannasoul \/ Synaptogenix"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Serina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Serina Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Serina Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Araris Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Araris Biotech \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Araris Biotech \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Prism Biolab","amount2":0.66000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Prism Biolab \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Prism Biolab \/ Eli Lilly"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Shape Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Shape Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Lycia Therapeutics"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company LLC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company LLC"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Relay Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Relay Therapeutics"},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Aqemia","amount2":0.14000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Aqemia \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Aqemia \/ Sanofi"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ The Benchmark Company"},{"orgOrder":0,"company":"Depixus","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Depixus","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Depixus \/ Daiichi Sankyo","highestDevelopmentStatusID":"2","companyTruncated":"Depixus \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Anagenex","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Anagenex","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Anagenex \/ Nimbus Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Anagenex \/ Nimbus Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"NVIDIA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ NVIDIA","highestDevelopmentStatusID":"3","companyTruncated":"Genentech \/ NVIDIA"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.24,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.24,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Moonwalk Biosciences","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Moonwalk Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Moonwalk Biosciences \/ Alpha Wave Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Moonwalk Biosciences \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"AbCheck","sponsor":"Ampersand Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CZECH REPUBLIC","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AbCheck","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"AbCheck \/ Ampersand Biomedicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCheck \/ Ampersand Biomedicines"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Biocytogen \/ Gilead Sciences"},{"orgOrder":0,"company":"InveniAI","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"InveniAI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"InveniAI \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"InveniAI \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"VantAI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"VantAI","amount2":0.67000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"VantAI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"AAV-mediated Gene Therapy","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"EVQLV","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"EVQLV","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"EVQLV \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"EVQLV \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Orbis Medicines \/ Novo Holding","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medicines \/ Novo Holding"},{"orgOrder":0,"company":"Leash Biosciences","sponsor":"Springtide Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leash Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Leash Biosciences \/ Springtide Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Leash Biosciences \/ Springtide Ventures"},{"orgOrder":0,"company":"Invenra","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Invenra \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Astellas Pharma"},{"orgOrder":0,"company":"MedinCell","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"MedinCell","amount2":1.9399999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":1.9399999999999999,"dosageForm":"Injection","sponsorNew":"MedinCell \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell \/ AbbVie Inc"},{"orgOrder":0,"company":"Vilya","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Macrocycle-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Vilya","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Vilya \/ ARCH Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Vilya \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Menten AI","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Peptide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Menten AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Menten AI \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Menten AI \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"ExpressionEdits","sponsor":"Octopus Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ExpressionEdits","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"ExpressionEdits \/ Octopus Ventures","highestDevelopmentStatusID":"3","companyTruncated":"ExpressionEdits \/ Octopus Ventures"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0.12,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Immunocan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Alpaca-derived Nanobody Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Immunocan","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Immunocan \/ Not Applicable","highestDevelopmentStatusID":"3","companyTruncated":"Immunocan \/ Not Applicable"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nabla Bio","sponsor":"Radical Ventures","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nabla Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Nabla Bio \/ Radical Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nabla Bio \/ Radical Ventures"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Pharma \/ Orbit Discovery"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Elsie Biotechnologies","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Elsie Biotechnologies \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Elsie Biotechnologies \/ GSK"},{"orgOrder":0,"company":"RevolKa","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"RK007","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ Daiichi Sankyo","highestDevelopmentStatusID":"1","companyTruncated":"RevolKa \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Isomorphic Labs","amount2":1.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.75,"dosageForm":"","sponsorNew":"Isomorphic Labs \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Isomorphic Labs \/ Eli Lilly"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Totus Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Totus Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"NEOsphere Biotechnologies","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"NEOsphere Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"NEOsphere Biotechnologies \/ Kymera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"NEOsphere Biotechnologies \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Enveda Bioscience \/ Microsoft","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Microsoft"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Oxford Nanopore Technologies","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Oxford Nanopore Technologies","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Oxford Nanopore Technologies"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Afrigen Biologics and Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Afrigen Biologics and Vaccines","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co \/ Afrigen Biologics and Vaccines"},{"orgOrder":0,"company":"Genexine","sponsor":"EPD Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ EPD Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Genexine \/ EPD Biotherapeutics"},{"orgOrder":0,"company":"Genomics plc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Genomics plc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Genomics plc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Genomics plc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Leveragen","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Leveragen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Leveragen \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Leveragen \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Medicilon","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Medicilon","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Medicilon \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Medicilon \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"SK Pharmteco","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"SK Pharmteco","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"SK Pharmteco \/ Rznomics","highestDevelopmentStatusID":"2","companyTruncated":"SK Pharmteco \/ Rznomics"},{"orgOrder":0,"company":"Lindy Biosciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Lindy Biosciences","amount2":0.94999999999999996,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Lindy Biosciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Protein-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Generate Biomedicines","amount2":1.0700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.0700000000000001,"dosageForm":"","sponsorNew":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Generate Biomedicines \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Syntekabio","sponsor":"Enamine Ltd","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SOUTH KOREA","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Syntekabio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Syntekabio \/ Enamine Ltd","highestDevelopmentStatusID":"3","companyTruncated":"Syntekabio \/ Enamine Ltd"},{"orgOrder":0,"company":"X-Chem","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"X-Chem","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"X-Chem \/ Evotec"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Genesis Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Genesis Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Genesis Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Unravel Biosciences","sponsor":"Jackson Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Unravel Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Unravel Biosciences \/ Jackson Laboratory","highestDevelopmentStatusID":"1","companyTruncated":"Unravel Biosciences \/ Jackson Laboratory"},{"orgOrder":0,"company":"Axcelead","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Axcelead \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Axcelead \/ Eli Lilly"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Laxxon Medical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ Laxxon Medical","highestDevelopmentStatusID":"2","companyTruncated":"Adare Pharma Solutions \/ Laxxon Medical"},{"orgOrder":0,"company":"Axcelead","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Axcelead","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Axcelead \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Axcelead \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Araris Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"FRANCE","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Araris Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Araris Biotech"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Belief BioMed \/ AskBio","highestDevelopmentStatusID":"3","companyTruncated":"Belief BioMed \/ AskBio"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Eurofins Discovery \/ Dompe Farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Terray Therapeutics","sponsor":"Bedford Ridge Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Terray Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.12,"dosageForm":"","sponsorNew":"Terray Therapeutics \/ Bedford Ridge Capital","highestDevelopmentStatusID":"3","companyTruncated":"Terray Therapeutics \/ Bedford Ridge Capital"},{"orgOrder":0,"company":"D-Wave Quantum","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"D-Wave Quantum","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"D-Wave Quantum \/ Japan Tobacco","highestDevelopmentStatusID":"3","companyTruncated":"D-Wave Quantum \/ Japan Tobacco"},{"orgOrder":0,"company":"Antiverse","sponsor":"i&i Biotech Fund I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Antiverse \/ i&i Biotech Fund I","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ i&i Biotech Fund I"},{"orgOrder":0,"company":"Gelteq","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gelteq","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Gelteq \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"Gelteq \/ The Benchmark Company"},{"orgOrder":0,"company":"Gelteq","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Gelteq","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Gelteq \/ The Benchmark Company","highestDevelopmentStatusID":"3","companyTruncated":"Gelteq \/ The Benchmark Company"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Alloy Therapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Scripps Research"},{"orgOrder":0,"company":"Antiverse","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Antiverse \/ Nxera Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ Nxera Pharma"},{"orgOrder":0,"company":"Converge Bio","sponsor":"TLV Partners","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Converge Bio","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.01,"dosageForm":"","sponsorNew":"Converge Bio \/ TLV Partners","highestDevelopmentStatusID":"3","companyTruncated":"Converge Bio \/ TLV Partners"},{"orgOrder":0,"company":"Institute for Protein Design","sponsor":"Vilya","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Macrocyclic Peptide","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Institute for Protein Design","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Institute for Protein Design \/ Vilya","highestDevelopmentStatusID":"3","companyTruncated":"Institute for Protein Design \/ Vilya"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Schrodinger","amount2":2.4199999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.4199999999999999,"dosageForm":"","sponsorNew":"Schrodinger \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Schrodinger \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"AI Proteins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Miniprotein-Based Therapeutics","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AI Proteins","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"AI Proteins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"AI Proteins \/ Bristol Myers Squibb"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AI Proteins

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            AI Proteins

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miniprotein-Based Therapeutics

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $400.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bristol Myers Squibb Taps AI Proteins in Drug Discovery Collaboration Worth Up to $400M

                            Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Miniprotein-Based Therapeutics

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $400.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Schrodinger

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Schrodinger

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,422.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Schrödinger Expands Collaboration with Novartis for Multi-Target Drug Discovery

                            Details : Through the collaboration, Schrodinger and Novartis will combine their research efforts to identify and advance therapeutics for undisclosed targets in Novartis’s core therapeutic areas.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : $150.0 million

                            November 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,422.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Antiverse

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Antiverse

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nxera And Antiverse Collaborate on GPCR Antibodies Using Generative AI

                            Details : The collaboration combines Antiverse’s AI antibody design expertise, including its epitope-specific libraries with Nxera’s NxWave platform, a powerful tool for GPCR target selection.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 05, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gelteq

                            Australia arrow
                            PharmaVenue
                            Not Confirmed

                            Gelteq

                            Australia arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : The Benchmark Company

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Gelteq Limited Closes US$5.2 Million Initial Public Offering

                            Details : The net proceeds from the offering for various purposes, including funding certain manufacturing, marketing and research and development activities.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : The Benchmark Company

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alloy Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Alloy Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Scripps Research

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Alloy And Scripps Partner on ATX-Gx™ Platform for Antibody Discovery

                            Details : The agreement provides Scripps Research scientists with broad access to Alloy’s fully human transgenic mouse platform, which has the power to increase the pace and success rate of antibody discovery.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Scripps Research

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Terray Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Terray Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Bedford Ridge Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Terray Therapeutics Closes $120M Series B for Small Molecule Therapeutics

                            Details : The funding will progress internal programs into clinical trials and further enhance Terray’s integrated AI platform, tNova, which it uses to power both internal and partnered programs.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 17, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bedford Ridge Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eurofins Discovery

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Eurofins Discovery

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eurofins Discovery Extends AI-powered Integrated Drug Discovery Collaboration

                            Details : The collaboration aims to combine strengths of Eurofins Discovery’s DiscoveryOne comprehensive Integrated Drug Discovery capabilities with Dompé’s powerful supercomputing AI platform.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            D-Wave Quantum

                            Country arrow
                            PharmaVenue
                            Not Confirmed

                            D-Wave Quantum

                            Country arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Japan Tobacco

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Japan Tobacco and D-Wave Partner for Drug Discovery with Quantum AI

                            Details : The collaboration aims to to revolutionize the speed and quality of Quantum AI-driven Drug Discovery, aimed at creating first-in-class small molecule pharmaceuticals.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Japan Tobacco

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Belief BioMed

                            China arrow
                            PharmaVenue
                            Not Confirmed

                            Belief BioMed

                            China arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

                            Details : Through the collaboration, the companies will combine efforts & experience in gene therapy technology to explore potential therapies in diseases that may be treatable using a liver-targeted approach.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 25, 2024

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : AskBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Generate Biomedicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Generate Biomedicines

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novartis Inks $1B-plus Biobucks Deal with Flagship's Generate

                            Details : The collaboration leverages Generate’s proprietary generative AI platform to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $65.0 million

                            September 24, 2024

                            Lead Product(s) : Protein-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $1,065.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth